Sonoma Pharmaceuticals (SNOA) Net Margin (2010 - 2025)
Sonoma Pharmaceuticals (SNOA) recorded quarterly Net Margin of 18.83% in Q4 2025, down 97.63% quarter-over-quarter from 9.53% in Q3 2025, and up 721.0% on a YoY basis from 2.29% in Q4 2024.
Sonoma Pharmaceuticals (SNOA) Net Margin (2010 - 2025) Analysis & Trends
Sonoma Pharmaceuticals' Net Margin history runs 16 years deep, the most recent figure standing at 18.83% for Q4 2025.
- In Q4 2025, Net Margin rose 721.0% year-over-year to 18.83%; the TTM figure through Dec 2025 stood at 19.02% (up 781.0% YoY), while the FY2025 annual figure was 24.2%, up 1377.0% from the prior year.
- Net Margin was 18.83% for Q4 2025 at Sonoma Pharmaceuticals, down from 9.53% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 2.67% in Q3 2021 to a low of 65.86% in Q4 2022.
- Historically, Net Margin has averaged 29.74% across 5 years, with a median of 29.8% in 2021.
- The sharpest annual moves came in 2021 and 2023: Net Margin sank 4626 bps in 2021, then surged 3827 bps in 2023.
- A 5-year view of Net Margin shows it stood at 2.67% in 2021, then sank by 2366 bps to 65.86% in 2022, then surged by 58 bps to 27.6% in 2023, then climbed by 6 bps to 26.04% in 2024, then rose by 28 bps to 18.83% in 2025.
- The last three Net Margin figures came in at 18.83% (Q4 2025), 9.53% (Q3 2025), and 30.91% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 9.19% |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 26.57% |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 35.18% |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 2.94% |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 24.30% |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 4.16% |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -168.42% |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -15.15% |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 31.38% |
| 10 | Sonoma Pharmaceuticals | 1.90 Mn | -659,569.98 | 1.65 Mn | -18.83% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -18.83% |
| Sep 30, 2025 | -9.53% |
| Jun 30, 2025 | -30.91% |
| Mar 31, 2025 | -20.67% |
| Dec 31, 2024 | -26.04% |
| Sep 30, 2024 | -17.04% |
| Jun 30, 2024 | -33.71% |
| Mar 31, 2024 | -31.03% |
| Dec 31, 2023 | -27.60% |
| Sep 30, 2023 | -54.34% |
| Jun 30, 2023 | -41.38% |
| Mar 31, 2023 | -43.40% |
| Dec 31, 2022 | -65.86% |
| Sep 30, 2022 | -30.53% |
| Jun 30, 2022 | -22.27% |
| Sep 30, 2021 | -2.67% |
| Jun 30, 2021 | -29.80% |
| Dec 31, 2020 | -0.49% |
| Sep 30, 2020 | -0.54% |
| Jun 30, 2020 | 16.46% |